Pipeline of Assets Available for Partnering Opportunities
The SapVax platform is a versatile and powerful tool for development of a pipeline of peptide-based cancer vaccines. SapVax’s lead NY-ESO-1 targeting candidate is in late-stage preclinical development with a near-term path to the clinic. SapVax’s SVX-NEO program to create personalized neoantigen vaccines is in the discovery stage. The SapVax vaccine approach has high potential for synergy with other novel immunotherapies, including combination with checkpoint inhibitors, neoantigen-targeting vaccines, and combination therapies with CAR-T and other cellular therapies.